News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

2008

  • Dec 16, 2008 Eldecalcitol, An Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial
    [PDF 34KB]
  • Dec 04, 2008 Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
    [PDF 27KB]
  • Dec 03, 2008 Conclusion of a joint research agreement between Chiome and Chugai: Innovation in the research and development of therapeutic antibodies by means of the revolutionary "ADLib® System" monoclonal antibody identification technology
    [PDF 31KB]
  • Nov 28, 2008 Approval of a New Indication for Oxarol® Ointment/Lotion (nonproprietary name: maxacalcitol), Psoriasis Vulgaris Treatment Topical Products Containing Active Vitamin D3, for Extended Treatment of Palmoplantar Pustulosis
    [PDF 50KB]
  • Nov 26, 2008 Anti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin® Application for Approval of Additional Indication of NSCLC
    [PDF 24KB]
  • Nov 25, 2008 RoACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Receives Positive Opinion in Europe for the Treatment of Rheumatoid Arthritis
    [PDF 24KB]
  • Nov 12, 2008 Extension of the Shelf Life for the Anti-influenza Agent, Tamiflu® Capsule 75, for the Purpose of Stockpiling by the Japanese Government as a Measure against New Influenza
    [PDF 55KB]
  • Oct 27, 2008 Data from Overseas Phase III Trial (LITHE) of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients
    [PDF 41KB]
  • Oct 21, 2008 Correction of Consolidated Company Performance (for the third quarter of fiscal year 2008.12 ended September 30, 2008)
    [PDF 44KB]
  • Oct 21, 2008 F. Hoffmann-La Roche Announces Third Quarter Sales 2008
    [PDF 62KB]
  • Oct 02, 2008 Chugai Hosts a Charity Concert Christmas Concert in Yokohama Featuring Star Philharmonic Chorus
    [PDF 92KB]
  • Sep 25, 2008 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 111KB]
  • Aug 07, 2008 Reconstruction Support for Areas Damaged by the Iwate-Miyagi Inland Earthquake 2008
    [PDF 70KB]
  • Jul 31, 2008 Toll Manufacturing Agreement for the Bulk Drug Substance of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody
    [PDF 44KB]
  • Jul 30, 2008 FDA Advisory Committee Votes in Favor to Recommend Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for Rheumatoid Arthritis
    [PDF 24KB]
  • Jul 22, 2008 Flash Report of the Interim Financial Results for the Fiscal Term ended June 30, 2008
    [PDF 81KB]
  • Jul 22, 2008 F. Hoffmann-La Roche Announces 2008 Half Year Results
    [PDF 26KB]
  • Jun 27, 2008 Establishment of "C gatakanen ( Hepatitis C) ZERO," a website for providing information on hepatitis C to the general public
    [PDF 519KB]
  • Jun 24, 2008 Announcement of Result on the Tender Offer for the Shares of Chugai Pharmaceutical Co., Ltd. by Roche Pharmholding B.V.
    [PDF 77KB]
  • Jun 16, 2008 Data from Overseas Phase III Trial (RADIATE and AMBITION) Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
    [PDF 83KB]
  • Jun 02, 2008 Reconstruction support for the devastating earthquake disaster area in Sichuan, China
    [PDF 71KB]
  • May 23, 2008 Announcement of an Opinion on the Tender Offer for the Shares of Chugai Pharmaceutical Co., Ltd.
    [PDF 255KB]
  • May 14, 2008 Co-Development and Co-Marketing Agreement Secured for the Activated Vitamin D Derivative, ED-71
    [PDF 77KB]
  • Apr 22, 2008 Revision of Financial Outlook for Fiscal Year 2008 (January 1 - December 31, 2008)
    [PDF 78KB]
  • Apr 17, 2008 F. Hoffmann-La Roche Announces First Quarter Sales 2008
    [PDF 36KB]
  • Apr 16, 2008 Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis
    [PDF 57KB]
  • Apr 02, 2008 Reinforcement of Structure for the European Sales Bases
    [PDF 54KB]
  • Feb 29, 2008 Anti-Cancer Agent Herceptin® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2
    [PDF 77KB]
  • Feb 29, 2008 Combination Therapy of Anti-Cancer Agents, Xeloda®, Elplat® and Avastin®, and Monotherapy of Xeloda® filed for Advanced or Recurrent Colorectal Cancer
    [PDF 56KB]
  • Jan 30, 2008 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2007
    [PDF 37KB]
  • Jan 11, 2008 Executive Announcement
    [PDF 20KB]
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top